Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2021

View Archived Issues

Blueprint Medicines to acquire LNG-451 with Lengo Therapeutics acquisition

Oncostatin M targeting as approach for treating inflammatory pruritus

Metabotropic glutamate mGlu2 receptor found to be associated with alcoholism

IBI-319, a novel CD137/PD-1 bispecific antibody with limited systemic toxicity

Shanghai Longwood Biopharmaceuticals divulges PD-1/PD-L1 interaction inhibitors

Dartmouth College discloses new GR antagonists

Txinno Bioscience presents new ENPP1 inhibitors

Eli Lilly and Company identifies CSF1R inhibitors

New RIPK1 inhibitors presented by National Institute of Pharmaceutical R&D

B-cell targeting controls chronic viral infections in mice

New transgenic hACE2-expressing mouse model shows efficacy of vaccine against brain COVID-19

Discovery of novel antifungal compounds with improved metabolic stability

PNV-2 reduces metastases in animal model of triple-negative breast cancer

Scorpion Therapeutics unveils lead programs in cancer

Polyphenylene carboxymethylene shows anti-SARS-CoV-2 activity in vitro

Janssen publishes PK/PD data for the anticoagulant-reversing agent JNJ-67842125

Indomethacin-based PROTACs show pan-coronavirus activity, including SARS-CoV-2 strains

NHD2 is essential in Leishmania independently of complex I, emerging as a potential drug target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...